Canadian Journal of Infectious Diseases and Medical Microbiology / 2019 / Article / Tab 1

Review Article

Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story

Table 1

Meningococcal conjugate and protein vaccines authorized for marketing and sale in Canada.

Brand nameCurrent distributorComposition: polysaccharide and carrier proteinAcronym used in manuscriptAuthorization date

Menjugate™GlaxoSmithKlineC with CRM197MenC-Con (CRM)September 2001
Neisvac-C™PfizerC with TTMenC-Con (TT)January 2002
Meningitec™Nuron BiotechC with CRM197MenC-Con (CRM)February 2004
Menactra™Sanofi PasteurACWY with DTMenACWY-Con (DT)October 2006
Menveo™GlaxoSmithKlineACWY with CRM197MenACWY-Con (CRM)July 2010
Nimenrix™PfizerACWY with TTMenACWY-Con (TT)August 2013
Bexsero™GlaxoSmithKlineNHBA, NadA, fHbp, and OMV (PorA P1.4)Men-Prot or 4CMenBDecember 2013
Trumenba™PfizerBivalent FHbpMen-Prot or MenB-FHbpJuly 2018

Withdrawn from marketing and authorization suspended in April 2014 following a problem with the production process.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.